Verastem, Inc. (VSTM)

Market Cap	235.50M
Revenue (ttm)	n/a
Net Income (ttm)	-87.37M
Shares Out	25.30M
EPS (ttm)	-3.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,623
Open	9.54
Previous Close	9.61
Day's Range	9.27 - 9.75
52-Week Range	4.32 - 15.12
Beta	0.53
Analysts	Strong Buy
Price Target	28.79 (+209.24%)
Earnings Date	May 7, 2024

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2012
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: VSTM

Analyst Forecast

According to 7 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price forecast is $28.79, which is an increase of 209.24% from the latest price.

Price Target

$28.79

(209.24% upside)

Analyst Consensus: Strong Buy